Prediction model for severity of diabetic retinopathy derived from review of endothelial dysfunction and hypoxia markers

Main Article Content

Ya.V. Sirman
I.V. Savytskyi
N.I. Preys

Abstract

Background. According to a wide range of authors, eye damage caused by diabetes mellitus accounts for 80–90 % of the total number of disorders. The development of mathematical predictive models allows for a more versatile analysis of experimental and clinical data. The purpose of the study was to develop a model for predicting the severity of diabetic retinopathy based on a review of markers of endothelial dysfunction and hypoxia. Materials and methods. We used a streptozotocin model of type 2 diabetes mellitus. Determined von Willebrand factor, endothelin-1, 2,3-diphosphoglycerate are used as variables. Also, the transition of the non-proliferative phase of diabetic retinopathy into the proliferative on the 180th day of the experiment was confirmed histologically. Results. We have developed a mathematical model for predicting the studied pathological state based on biochemical blood tests at the early stages of the experiment. We have proven the informative value of endothelial dysfunction markers, von Willebrand factor and endothelin-1, for predicting the transition of non-proliferative diabetic retinopathy into the proliferative phase. We determined the significance of a comprehensive analysis of the level of 2,3-diphosphoglycerate in erythrocytes together with the above markers of the functional status of the endothelium on day 30 for predicting the further course of the disease. Conclusions. We determined the effectiveness of a comprehensive analysis of the level of 2,3-diphosphoglycerate in erythrocytes together with the above markers of the functional status of the endothelium on day 30 for predicting the further course of the pathological process under study.

Article Details

How to Cite
Sirman, Y., I. Savytskyi, and N. Preys. “Prediction Model for Severity of Diabetic Retinopathy Derived from Review of Endothelial Dysfunction and Hypoxia Markers”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 1, Apr. 2021, pp. 76-80, doi:10.22141/2224-0721.17.1.2021.226435.
Section
Original Researches

References

Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci. 2018 Jun 20;19(6):1816. doi:10.3390/ijms19061816.

Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018 Dec;18(12):1257-1270. doi:10.1080/14712598.2018.1545836.

Bandello F, Lattanzio R, Zucchiatti I, Del Turco C. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013 Feb;50(1):1-20. doi:10.1007/s00592-012-0449-3.

Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. 2013 Jan 15;2013:343560. doi:10.1155/2013/343560.

Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64. doi:10.2337/dc11-1909.

Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273. doi:10.1155/2016/2156273.

Gonzalez VH, Campbell J, Holekamp NM, et al. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. Am J Ophthalmol. 2016 Dec;172:72-79. doi:10.1016/j.ajo.2016.09.012.

Bek T. Diameter Changes of Retinal Vessels in Diabetic Retinopathy. Curr Diab Rep. 2017 Aug 8;17(10):82. doi:10.1007/s11892-017-0909-9.

Nentwich MM, Ulbig MW. Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes. 2015 Apr 15;6(3):489-99. doi:10.4239/wjd.v6.i3.489.

Karlberg C, Falk C, Green A, Sjølie AK, Grauslund J. Proliferative retinopathy predicts nephropathy: a 25-year follow-up study of type 1 diabetic patients. Acta Diabetol. 2012 Aug;49(4):263-8. doi:10.1007/s00592-011-0304-y.

Kramer CK, Retnakaran R. Concordance of retinopathy and nephropathy over time in Type 1 diabetes: an analysis of data from the Diabetes Control and Complications Trial. Diabet Med. 2013 Nov;30(11):1333-41. doi:10.1111/dme.12296.

Pasechnikova NV, Moroz OA. Protective action of quercetin and lipoate on functional groups of retinal proteins under simulated diabetes. Journal of Ophthalmology. 2015;3:76-81. doi:10.31288/oftalmolzh201537681.

Kaydash OA, Ivanov VV, Vengerovsky AI, Buyko EE, Schepetkin IA. The experimental model of type 2 diabetes mellitus caused by a high-fat diet with low-dose streptozotocin in rats. Bulletin of Siberian Medicine. 2020;19(2):41-47. doi:10.20538/1682-0363-2020-2-41-47.

Reinhart K, Bayer O, Brunkhorst F, Meisner M. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med. 2002 May;30(5 Suppl):S302-12. doi:10.1097/00003246-200205001-00021.

He S, Blombäck M, Wallén H, Jeppsson A, Grass S. Global impairments in the haemostasis systems after cardiopulmonary bypass. Thromb Res. 2017 Mar;151:63-66. doi:10.1016/j.thromres.2017.01.006.

Marasciulo FL, Montagnani M, Potenza MA. Endothelin-1: the yin and yang on vascular function. Curr Med Chem. 2006;13(14):1655-65. doi:10.2174/092986706777441968.

Scott AV, Nagababu E, Johnson DJ, et al. 2,3-Diphosphoglycerate Concentrations in Autologous Salvaged Versus Stored Red Blood Cells and in Surgical Patients After Transfusion. Anesth Analg. 2016 Mar;122(3):616-23. doi:10.1213/ANE.0000000000001071.

Nosko VP. Econometrics: Book 2, Part 3, 4. Moscow: Delo; 2011. 576 p. (in Russian).

Basilevich KA, Mazorchuk MS, Sukhobrus AA. Modelling in economy, arrangement of production and project management. Information processing systems. 2016:2(139):149-155. (in Russian).

Sorrentino FS, Matteini S, Bonifazzi C, Sebastiani A, Parmeggiani F. Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction. Eye (Lond). 2018 Jul;32(7):1157-1163. doi:10.1038/s41433-018-0032-4.

Siemianowicz K, Francuz T, Gminski J, Telega A, Syzdól M. Endothelium dysfunction markers in patients with diabetic retinopathy. Int J Mol Med. 2005 Mar;15(3):459-62.